My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

7.470 -0.240 (-3.11%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

What 8 Analyst Ratings Have To Say About Vir Biotechnology ↗

April 04, 2023

Via Benzinga

Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information ↗

March 21, 2023

Via Benzinga

Biotech Stocks And The SVB Collapse — Here's What We Know ↗

March 14, 2023

The collapse of SVB will have a big impact on early-stage, venture-backed companies.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023 ↗

March 06, 2023

Via Benzinga

Where Vir Biotechnology Stands With Analysts ↗

February 24, 2023

Via Benzinga

Vir Biotechnology's Earnings Outlook ↗

February 22, 2023

Via Benzinga

Overview Of Value Stocks In The Healthcare Sector ↗

February 20, 2023

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

January 30, 2023

Via Benzinga

Vir Biotechnology Gets Price Targets Cuts By Analysts After Q4 Results ↗

March 06, 2023

Vir Biotechnology, Inc. (NASDAQ: VIR) reported worse-than-expected Q4 results. Vir Biotechnology posted a Q4 loss of $0.76 per share, versus market expectations of $0.39 per share. The company’s...

Via Benzinga

The Top 7 Growth Stocks in Biotech ↗

March 03, 2023

The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 23, 2023

Via Benzinga

NVIDIA To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday ↗

February 23, 2023

Goldman Sachs boosted the price target for Vir Biotechnology, Inc. (NASDAQ: VIR) from $41 to $53. Goldman Sachs analyst Paul Choi maintained a Buy rating on the stock. Vir Biotechnology shares rose...

Via Benzinga

Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 21, 2023

Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.

Via Benzinga

Earnings Scheduled For February 23, 2023 ↗

February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

Via Benzinga

Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday ↗

February 21, 2023

U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 ↗

February 21, 2023

Via Benzinga

DraftKings To Rally Around 38%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

February 21, 2023

Wells Fargo boosted the price target for Deere & Company (NYSE: DE) from $485 to $510. Wells Fargo analyst Seth Weber maintained an Overweight rating on the stock. Deere shares fell 0.5% to $431.08 in...

Via Benzinga

Analyst Expectations for Vir Biotechnology's Future ↗

January 27, 2023

Via Benzinga

2 Fast-Growing Healthcare Stocks to Buy and Hold ↗

December 02, 2022

The innovative companies have made great gains in a short period of time.

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 21, 2023

Via Benzinga

Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out ↗

February 14, 2023

Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020.

Via Benzinga

Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

February 14, 2023

Don’t forget to check out our premarket coverage here Fate Therapeutics, Inc. (NASDAQ: FATE) fell 4.1% to $6.13 in pre-market trading. Fate Therapeutics is expected to report Q4 results on Tuesday,...

Via Benzinga

Insiders Selling Meta Platforms And 3 Other Stocks ↗

February 10, 2023

The Nasdaq dropped by more than 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

The 7 Most Undervalued Biotech Stocks to Buy in February 2023 ↗

February 02, 2023

Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy.

Via InvestorPlace

7 Healthcare Stocks That Will Be Big Winners in 2023 ↗

January 31, 2023

Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023 ↗

January 27, 2023

Via Benzinga

2 Stocks That Could Turn $100 Into $1,000 by 2028 ↗

January 22, 2023

These growth stocks have substantial tailwinds.

Via The Motley Fool

BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts ↗

December 02, 2022

Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding...

Via Benzinga

European Official Says COVID-19 Booster Uptake Disappointing In The Region ↗

November 25, 2022

Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather...

Via Benzinga

After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade ↗

November 18, 2022

Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.